Sherko Kuemmel
Kliniken Essen-Mitte
Research areas: Medicine · Oncology · Breast Cancer Treatment Studies · HER2/EGFR in Cancer Research · Breast Lesions and Carcinomas
0000-0001-9355-494X
About
Biographical Sketch Sherko Kuemmel
Date of birth: February 28th, 1971
Place of birth: Berlin, Germany
Dissertation Degree with „Magna cum laude“ at University Hospital Charité, Department of Radiology (Director – Prof. Dr. med. Dr. h.c. R.Felix) - Prof. Dr. med. T. Vogl to the topic: Dynamic and Static Gd-EOB-DTPA-enhanced MRI in primary and secondary liver tumors: Comparison with Gd-DTPA enhanced MRI in the same patient.
Education:
9/1991-8/1993 Premedical School (Physicum), Humboldt-University, University-Hospital Charité, Berlin, Germany
9/1993-8/1997 MD, Humboldt-University, University-Hospital Charité, Berlin, Germany
8/2000 Approbation
Postgraduate Training:
01/1998-12/1998 Scientific Assistant, Department of Gynecology and Obstetrics, Hospital Lichtenberg-Berlin (Director – Prof. D. Elling)
1/1999-7/2002 Resident, Department of Gynecology and Obstetrics, Hospital Lichtenberg-Berlin (Director – Prof. Dr. med. D. Elling)
08/2002 –12/2003 Resident, Department of Gynecology and Obstetrics, University hospital Charité (Director: Prof. Dr. med. W. Lichtenegger)
01/2004-4/2005 Junior faculty, Department of Gynecology and Obstetrics, University hospital Charité (Director: Prof. Dr. med. W. Lichtenegger)
01/2005 Medical specialization on obstetrics and gynecology
11/2002-03/2006 Chairman of the scientific laboratory, Department of Gynecology and Obstetrics, University hospital Charité, Campus Mitte
05/05 – 03/ 2006 Assistant Medical Director
Department of Gynecology and Obstetrics, University hospital Charité (Director: Prof. Dr. Lichtenegger)
Chairman of the study center, Department of Gynecology and Obstetrics, University hospital Charité, Campus Mitte
4/2006 – 12/2009 Assistant Medical Director - Department of Gynecology and Obstetrics, University hospital Essen (Director: Prof. Dr. med. R. Kimmig)
12/2006 - 12/2009 Coordination and supervision of the
„University-Breast-Centre Essen“
12/2006 - 12/2009 Coordination and supervision of the tumorconference of the breast center
12/2006 - 12/2009 Coordination and supervision of the working group for clinical studies for the „University- Breast-Center Essen
01/2010 – present Director Interdisciplinary Breast Center; Kliniken Essen-Mitte
Emphasis :
Therapy of local and advanced breast cancer, including whole spectrum of operative and systemic therapy
Operative Senology
Clinical studies (phase I-IV) for evaluation of new cytostatic substances and its combinations and surgical studies for Breast Cancer therapy since 1997
Leading Principal Investigator for clinical trials and
translational research programs
Advisory Board for different studies
Steering committe for different studies
IDMC Member for different studies
Clinical rotations in foreign countries:
03/1997-07/1997 Clinical rotation, Internal medicine, Yale University Medical Center, New Haven/CT and University of Texas, Houston/Tx – Cardiology
12/1999 Observer ship, Memorial Sloan Kettering Cancer Center, NY (Breast Cancer Medicine Dept. – Dir.: Prof. L. Norton)
Memberships:
ASCO Full Membership (American Society of Clinical Oncology)
AGO (Arbeitsgemeinschaft Gynäkologische Onkologie)
Berlin Society of Gynecology
Scientific Board for locoregional therapy of the GBG
(German Breast Group)
Scientific Board for Surgical Therapy of the GBG
(German Breast Group)
DKG (German Cancer Society)
DGGG (German Society of Gynecology and Obstetrics)
DEGUM (Dt. Gesellschaft für Ultraschall i.d. Medizin)
Executive Committee AGIM
(Arbeitsgemeinschaft Integrative Medizin)
NOGGO (NorthEast-German Society of Gynecological Oncology)
Publications:
94 peer reviewed publications as first or co-author
15 book chapters
172 abstracts
454 talks
Essen, 01.05.2014 Dr. med. S. Kümmel
Employment
-
Kliniken Essen-Mitte Director2010 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (69)
- Ultrasound-Visible 3D Nickel–Titanium Clip for Tumor Localization After Neoadjuvant Therapy in Early Breast Cancer: A Prospective Multicenter Real-World Study Save
- Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer Save
- A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Data from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S3 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S4 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S5 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S6 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S7 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S8 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Figure S9 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Material S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Table S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Supplementary Table S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors Save
- Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry Save
- "Supplementary Table S5 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial Save
- "Supplementary Table S6 from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial Save
- Data from Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial Save